SCHEMBL802481 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	CYP1A2	P05177	9/20	0.46

▸	CYP2D6	P10635	6/20	0.46

▸	CYP3A4	P08684	5/20	0.46

▸	MAPK1	P28482	1/20	0.46

▸	CYP2C19	P33261	6/20	0.41

▸	TSHR	P16473	3/20	0.41

▸	HSD17B10	Q99714	3/20	0.41

▸	KDM4E	B2RXH2	3/20	0.41

▸	ALDH1A1	P00352	3/20	0.41

▸	TDP1	Q9NUW8	1/20	0.41

▸	USP1	O94782	3/20	0.40

▸	WDR48	Q8TAF3	3/20	0.40

▸	CNR2	P34972	1/20	0.38

▸	USP2	O75604	1/20	0.38

▸	RECQL	P46063	1/20	0.38

▸	MEN1	O00255	2/20	0.38

▸	KMT2A	Q03164	2/20	0.38

▸	CLK4	Q9HAZ1	1/20	0.38

▸	TRPV4	Q9HBA0	2/20	0.37

▸	LMNA	P02545	1/20	0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13107230	0.87	HTR6 (0.39)	CYP1A2CYP2D6CYP3A4HSD17B10ALDH1A1
SCHEMBL801841	0.83	CYP1A2 (0.48)	CYP1A2CYP2D6CYP3A4MAPK1CYP2C19
SCHEMBL13055030	0.82	TRPV4 (0.36)	USP2MEN1KMT2ATRPV4LMNA
SCHEMBL10266769	0.81	USP1 (0.45)	CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL786461	0.81	USP1 (0.46)	CYP1A2CYP2D6CYP3A4MAPK1CYP2C19
SCHEMBL786698	0.79	USP1 (0.62)	CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL802061	0.79	USP1 (0.51)	CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL786482	0.78	CYP1A2 (0.45)	CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL802119	0.75	CYP1A2 (0.43)	CYP1A2CYP2D6CYP3A4CYP2C19TSHR
SCHEMBL802488	0.75	USP1 (0.43)	CYP1A2CYP2D6CYP3A4CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8633210-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2014-01-21	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-8524720-B2	Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2013-09-03	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2012-03-22	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-7951820-B2	Triazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2011-05-31	—	—	US	disclosed
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-10-07	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7691853-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2010-04-06	—	—	US	disclosed
US-7473691-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-01-06	—	—	US	disclosed
US-7473691-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-01-06	—	—	US	disclosed
US-7390815-B2	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED (US)	2008-06-24	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	VERTEX PHARMACEUTICALS INCORPORATED	2007-11-22	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20100256170-A1	PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, CDK3, GSK3A	CYP1A2 1818/4885CYP2D6 3096/4885CYP3A4 1976/4885
US-20120071657-A1	TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS	GSK3B, GSK3A, CDK19	CYP1A2 3042/4885CYP2D6 4165/4885CYP3A4 2929/4885
US-20070270444-A1	Pyrazole compounds useful as protein kinase inhibitors	GSK3B, CDK3, GSK3A	CYP1A2 1818/4885CYP2D6 3096/4885CYP3A4 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.